News | Structural Heart Occluders | March 27, 2019

SCAI Offers Recommendations for Safe Use of PFO Closure Technologies

Completion of the randomized trials demonstrating the superiority of PFO closure and medical therapy over medical therapy alone 

SCAI Offers Recommendations for Safe Use of PFO Closure Technologies. SCAI said completion of the randomized trials demonstrating the superiority of PFO closure and medical therapy over medical therapy alone

March 27. 2019 — A newly released expert consensus statement provides recommendations for the safe and effective dissemination of newly approved patent foramen ovale (PFO) closure technologies. The document, developed by the Society for Cardiovascular Angiography and Interventions (SCAI) and affirmed by the American Academy of Neurology (AAN), was published online in SCAI’s official journal, Catheterization and Cardiovascular Interventions.

Access the full text of the "SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke.[1]

Nearly 25 percent of the general population may have a PFO, which is an opening between the top left and right chambers of the heart. Closure of the PFO is one strategy in mitigating the risk of recurrent stroke in PFO patients who have experienced a cryptogenic stroke. Stroke is the fifth most common cause of death and the leading cause of preventable disability in the United States.

“Completion of the randomized trials demonstrating the superiority of PFO closure and medical therapy over medical therapy alone for appropriately selected patients with cryptogenic stroke and a PFO was a landmark achievement that has resolved decades of uncertainty,” said Eric Horlick, M.D., FSCAI, chair of the paper’s writing group and an interventional cardiologist at the Peter Munk Cardiac Centre, University of Toronto.

The writing group makes specific recommendations in the paper for operator competencies and training, facility infrastructure, multidisciplinary collaboration, and quality assessment measures. “The appropriate use of PFO closure has the potential to change the natural history of a potentially devastating disease process. SCAI and AAN representatives collaborated to help cardiologists and neurologists provide the highest standard of care,” Horlick said.

“SCAI can now confidently offer evidenced-based recommendations for the treatment of these patients, who are seeking answers to guide their therapeutic decision making after a potentially catastrophic event. I am very proud of the work produced by our dedicated and highly experienced SCAI writing group, including representatives from the AAN. The resulting document is pragmatic and aims to inform and assist clinicians and institutions in maintaining an evidenced-based, patient-centered approach to the care of this patient population with a focus on quality and safety.,” he continued.

The U.S. Food and Drug Administration (FDA) recently approved two percutaneous PFO occluder devices. Prior to approval, closure devices had only been available off-label through a humanitarian device exemption, and in randomized clinical trials. Now approved, the devices are widely available.

 

Related PFO Closure Content:

VIDEO: How Transcatheter PFO Closure Can Reduce Cryptogenic Stroke — Interview with John Rhodes, M.D.

VIDEO: An Overview of PFO Closure to Treat Cryptogenic Stroke — Interview with Karen Orjuela, M.D.

VIDEO: Transcatheter Closure of Holes in the Heart — Interview with Ziyad Hijazi, M.D.

VIDEO: Demonstration of a Transcatheter PFO Occluder Implantation

VIDEO: Addressing Adult Congenital Heart Referrals — Interview with Ami Bhatt, M.D.

 

Reference:

1. Eric Horlick, Clifford J. Kavinsky, Zahid Amin, et al. SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke. Catheterization and Cardiovascular Interventions. First published online 21 March 2019. https://doi.org/10.1002/ccd.28111

 

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021